Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).
about
Establishment of a new quality control and vaccine safety test for influenza vaccines and adjuvants using gene expression profilingMatrix and backstage: cellular substrates for viral vaccinesVaccines: the Fourth CenturyAdaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness.Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (OptafluĀ®): an open label, uncontrolled study.Seasonal influenza vaccination and technologies.All-in-one bacmids: an efficient reverse genetics strategy for influenza A virus vaccines.Current and emerging cell culture manufacturing technologies for influenza vaccines.Host Adaptation and the Alteration of Viral Properties of the First Influenza A/H1N1pdm09 Virus Isolated in JapanContinuous cell lines as a production system for influenza vaccines.Development and strategies of cell-culture technology for influenza vaccine.Metabolic and kinetic analyses of influenza production in perfusion HEK293 cell cultureNew strategies for the development of H5N1 subtype influenza vaccines: progress and challenges.Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production.Production of avian influenza virus vaccine using primary cell cultures generated from host organs.Synthetic generation of influenza vaccine viruses for rapid response to pandemics.Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells.Effects of egg-adaptation on receptor-binding and antigenic properties of recent influenza A (H3N2) vaccine viruses.RNA virus reverse genetics and vaccine design.Effect of influenza virus infection on key metabolic enzyme activities in MDCK cells.Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells.Impact of cultivation conditions on N-glycosylation of influenza virus a hemagglutinin produced in MDCK cell culture.High yield production of influenza virus in Madin Darby canine kidney (MDCK) cells with stable knockdown of IRF7Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccinationHeterogeneity of the MDCK cell line and its applicability for influenza virus researchVaccine production, distribution, access, and uptake.Development of an Influenza A Master Virus for Generating High-Growth Reassortants for A/Anhui/1/2013(H7N9) Vaccine Production in Qualified MDCK Cells.Failure-to-thrive syndrome associated with tumor formation by Madin-Darby canine kidney cells in newborn nude mice.Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study.Influenza vaccines: unmet needs and recent developments.Human influenza vaccines and assessment of immunogenicity.The future of cell culture-based influenza vaccine production.Adjuvanted influenza vaccines.Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.Flucelvax (Optaflu) for seasonal influenza.Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology.Production of canine adenovirus type 2 in serum-free suspension cultures of MDCK cells.Real-time monitoring of influenza virus production kinetics in HEK293 cell cultures.Egg-Independent Influenza Vaccines and Vaccine CandidatesTrypsin promotes efficient influenza vaccine production in MDCK cells by interfering with the antiviral host response.
P2860
Q21131780-D9385112-38C8-463D-8D58-995C3F3E4938Q27025941-FBCEACAC-1485-4ACC-84E6-EBEFFDA665C1Q27490454-ADC65576-8ADD-4222-B4CE-693626250334Q30224923-5E3C6D6C-7B41-4418-87F5-4A7B9764F2EFQ30355688-F0A5B1A4-78A1-4DDF-AB5B-1D1B6F5234CDQ30360897-2F3188C8-5B33-4534-95BE-BE0BEE1D8D74Q30363730-57FEE342-D5E2-4E47-B717-76959BE7A8BAQ30373128-86700574-9C0B-4817-A9A5-01864E9675E2Q30375713-6FABC7DE-A20F-4995-81CE-3D07DF1ACFF8Q30382947-9CFF52FD-A8D0-4E64-8914-4508ED1B9693Q30396047-CA1C56F6-5DDC-422D-B8DF-001FDE604736Q30406617-0210184B-2AB0-413E-834B-5E288549DF40Q30407424-3D07A492-982D-49FC-9F24-287B265A2905Q30419591-8E93BF04-F37A-4923-8F1B-B78B828FFEEFQ30428538-A5E801F8-945B-444D-AF84-F45332C4C7C4Q30430578-264E077A-1F3C-4C7D-A3ED-29EA2643D050Q30474419-1EB8393E-D03B-4AAB-B77A-A944B6FC6C4DQ33573489-2468D711-E6D8-4AB7-ACEA-6729132E2975Q33963398-3B64121A-9D46-47CF-8F44-347714A9AB54Q34176564-FDE7B053-99A3-4322-90E6-45F212681E9FQ34461309-8CCCC7E7-1A0C-42E3-BE2D-023DC61D7A3DQ34538848-BC04B53F-FEED-41DC-92CD-6DE3A2803636Q34652542-43E32227-C262-4733-BF40-7FFD3A70CABAQ34970364-659E5039-3D4F-4467-B263-B44A59D8CC1FQ34994947-73273EE6-6BC8-456D-B4AF-9DB079C786DEQ35188985-5BAB3B38-9C45-4A53-BEA9-383829D9BCFAQ36084675-EDA30BC8-FC1C-41B8-8404-5AE5556D6A96Q37113809-E7CD00F6-D3F8-4B4B-B4CB-A748AB6B77B7Q37264968-D3568A04-2759-4912-9A9B-2AE3CB5D890DQ37518273-8455C14E-17CC-41E5-9A1D-1EE9522CFDADQ37812125-0A164F1F-EA66-4F43-A5AF-5801AD1E3AD5Q37919896-44F80339-3E76-4F1E-B49B-3EFD663B7024Q38140045-239173CE-F057-4AE4-8A71-1B738D1BDFB9Q38157590-23B644AB-EAB7-45D8-84CE-AFAEA431AB65Q38476345-DC8930B7-94F1-4C56-8693-D8DEA632ED7CQ38554795-0DA02D25-92F5-4F6F-AB2C-5DB6D0610B92Q38872811-6ECD49DD-D4F9-44E0-84A4-47D0CCD17927Q39305309-743A48FF-B187-426E-87A0-86CC70EB2484Q39441518-964B8612-C986-43E1-8A76-E73421597CD1Q39474200-71183757-BC28-4DCA-B352-675189EFDFF9
P2860
Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).
description
2009 nĆ® lÅ«n-bĆ»n
@nan
2009 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« Õ
ÕøÖÕ¶Õ«Õ½Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2009 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ°ÕøÖÕ¶Õ«Õ½Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2009幓ć®č«ę
@ja
2009幓å¦ęÆęē«
@wuu
2009幓å¦ęÆęē«
@zh-cn
2009幓å¦ęÆęē«
@zh-hans
2009幓å¦ęÆęē«
@zh-my
2009幓å¦ęÆęē«
@zh-sg
2009幓åøč”ęē«
@yue
name
Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).
@ast
Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).
@en
Trivalent MDCK cell culture-derived influenza vaccine Optaflu
@nl
type
label
Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).
@ast
Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).
@en
Trivalent MDCK cell culture-derived influenza vaccine Optaflu
@nl
prefLabel
Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).
@ast
Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).
@en
Trivalent MDCK cell culture-derived influenza vaccine Optaflu
@nl
P2860
P356
P1476
Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).
@en
P2093
Alexander Doroshenko
P2860
P304
P356
10.1586/ERV.09.31
P577
2009-06-01T00:00:00Z